Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib / II Trial of Tarloxotinib and Sotorasib in Patients With KRAS G12C Mutations

NCT05313009 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT05313009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05313009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib / II Trial of Tarloxotinib and Sotorasib in Patients With KRAS G12C Mutations
Lead sponsor
Medical University of South Carolina
Phase
Phase 1/2
Overall status
Terminated
Start date
March 7, 2022
Completion date
December 31, 2023
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer